1QHR
NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QHR の概要
| エントリーDOI | 10.2210/pdb1qhr/pdb |
| 分子名称 | ALPHA THROMBIN, HIRUGEN, 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE, ... (5 entities in total) |
| 機能のキーワード | proteinase, blood coagulation, trypsin like proteinase, complex (serine protease-inhibitor), blood clotting-hydrolase inhibitor complex, blood clotting/hydrolase inhibitor |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| 細胞内の位置 | Secreted, extracellular space: P00734 P00734 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 35466.47 |
| 構造登録者 | Jhoti, H.,Cleasby, A.,Reid, S.,Thomas, P.,Wonacott, A. (登録日: 1999-05-26, 公開日: 2000-05-31, 最終更新日: 2024-10-30) |
| 主引用文献 | Jhoti, H.,Cleasby, A.,Reid, S.,Thomas, P.J.,Weir, M.,Wonacott, A. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. Biochemistry, 38:7969-7977, 1999 Cited by PubMed Abstract: The binding modes of four active site-directed, acylating inhibitors of human alpha-thrombin have been determined using X-ray crystallography. These inhibitors (GR157368, GR166081, GR167088, and GR179849) are representatives of a series utilizing a novel 5, 5-trans-lactone template to specifically acylate Ser195 of thrombin, resulting in an acyl complex. In each case the crystal structure of the complex reveals a binding mode which is consistent with the formation of a covalent bond between the ring-opened lactone of the inhibitor and residue Ser195. Improvements in potency and selectivity of these inhibitors for thrombin are rationalized on the basis of the observed protein/inhibitor interactions identified in these complexes. Occupation of the thrombin S2 and S3 pockets is shown to be directly correlated with improved binding and a degree of selectivity. The binding mode of GR179849 to thrombin is compared with the thrombin/PPACK complex [Bode, W., Turk, D., and Karshikov, A. (1992) Protein Sci. 1, 426-471] as this represents the archetypal binding mode for a thrombin inhibitor. This series of crystal structures is the first to be reported of synthetic, nonpeptidic acylating inhibitors bound to thrombin and provides details of the molecular recognition features that resulted in nanomolar potency. PubMed: 10387040DOI: 10.1021/bi9830359 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






